Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First Of Its Kind: Beam Seeks To Erase-And-Replace Single Letters In DNA's Alphabet

Executive Summary

Beam Therapeutics combines new insights from gene-editing pioneers to allow for single-letter editing of DNA and RNA. The company has raised $87m to develop DNA base-editing for therapies that in some diseases could be more efficient than CRISPR gene editing.


Related Content

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies
Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts